Skip to main content

Advertisement

SpringerLink
Log in

Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The therapeutic goals are palliative for metastatic breast cancer (MBC) and include prolongation of survival with good quality of life (QoL) and symptom control. The purpose of this study was to examine QoL among women with MBC treated on KCSG-BR07-02 with maintenance of paclitaxel plus gemcitabine (PG) chemotherapy after achieving disease control to initial six cycles of PG chemotherapy or observation. Patients were randomized to either maintenance chemotherapy or observation until progression. QoL was assessed using EORTC QLQ-C30 and BR-23. QoL at each cycle was compared between the two treatment arms using the 2-sample t test. Generalized estimating equation method was used to examine the overall difference between the two treatments in QoL. All reported p-values are 2 sided. There were no statistically significant differences between two arms in most of the component of the EORTC QLQ-C30 and BR-23 (p > 0.05). There was no significant difference between two treatments (p = 0.6094 for QLQ-C30, p = 0.5516 for BR23) at baseline, and there did not exist significant change over the cycle (p = 0.0914 for QLQ-C30, p = 0.7981 for BR23). There was no significant interaction effect between treatment and cycle (p = 0.5543 for QLQ-C30. p = 0.5817 for BR23). Maintenance PG chemotherapy in patients with MBC achieving disease control with an initial six cycles of PG chemotherapy resulted in better PFS and OS compared to observation without impeding QoL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA (2003) Health-related quality-of-life measurement in randomized clinical trials in breast cancer–taking stock. J Natl Cancer Inst 95:263–281

    Article  PubMed  Google Scholar 

  2. Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S, Theberge V (2011) Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009). J Natl Cancer Inst 103:178–231. doi:10.1093/jnci/djq508

    Article  PubMed  Google Scholar 

  3. Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, Klijn J, Van Hoorebeeck I, Paridaens R (2000) Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36:1498–1506

    Article  CAS  PubMed  Google Scholar 

  4. Coates A, Gebski V, Signorini D, Murray P, McNeil D, Byrne M, Forbes JF (1992) Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 10:1833–1838

    Article  CAS  PubMed  Google Scholar 

  5. Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, Coleman RE, Calvert HA, Gamucci T, Twelves C, Fargeot P, Bottomley A (2004) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40:1021–1030. doi:10.1016/j.ejca.2004.01.014

    Article  CAS  PubMed  Google Scholar 

  6. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L (2004) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22:2061–2068. doi:10.1200/jco.2004.08.048

    Article  CAS  PubMed  Google Scholar 

  7. Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, Osoba D, Bjordal K, Bottomley A (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10:865–871. doi:10.1016/s1470-2045(09)70200-1

    Article  PubMed  Google Scholar 

  8. Lee CK, Stockler MR, Coates AS, Gebski V, Lord SJ, Simes RJ (2010) Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. Br J Cancer 102:1341–1347. doi:10.1038/sj.bjc.6605649

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14:2756–2768

    Article  CAS  PubMed  Google Scholar 

  10. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376

    Article  CAS  PubMed  Google Scholar 

  11. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144

    Article  CAS  PubMed  Google Scholar 

  12. Ejlertsen B, Pfeiffer P, Pedersen D, Mouridsen HT, Rose C, Overgaard M, Sandberg E, Kristensen B (1993) Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29:527–531

    Article  Google Scholar 

  13. Muss HB, Case LD, Richards F 2nd, White DR, Cooper MR, Cruz JM, Powell BL, Spurr CL, Capizzi RL (1991) Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 325:1342–1348. doi:10.1056/nejm199111073251904

    Article  CAS  PubMed  Google Scholar 

  14. Falkson G, Gelman RS, Pandya KJ, Osborne CK, Tormey D, Cummings FJ, Sledge GW, Abeloff MD (1998) Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 16:1669–1676

    Article  CAS  PubMed  Google Scholar 

  15. Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R, Tattersall MH, Byrne M, Harvey V, Gill G (1987) Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317:1490–1495. doi:10.1056/nejm198712103172402

    Article  CAS  PubMed  Google Scholar 

  16. Harris AL, Cantwell BM, Carmichael J, Wilson R, Farndon J, Dawes P, Ghani S, Evans RG (1990) Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 335:186–190

    Article  CAS  PubMed  Google Scholar 

  17. Nooij MA, de Haes JC, Beex LV, Wildiers J, Klijn J, Becquart D, Jassem J, Engelsman E, Duchateau L (2003) Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Clinical outcomes and oncologists’ preferences. Eur J Cancer 39:614–621

    Article  CAS  PubMed  Google Scholar 

  18. Gennari A, Amadori D, De Lena M, Nanni O, Bruzzi P, Lorusso V, Manzione L, Conte PF (2006) Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24:3912–3918. doi:10.1200/jco.2006.06.1812

    Article  CAS  PubMed  Google Scholar 

  19. Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, Wilcken N, D’Amico M, DeCensi A, Bruzzi P (2011) Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 29:2144–2149. doi:10.1200/jco.2010.31.5374

    Article  PubMed  Google Scholar 

  20. Alba E, Ruiz-Borrego M, Margeli M, Rodriguez-Lescure A, Sanchez-Rovira P, Ruiz A, Mel-Lorenzo JR, Ramos-Vazquez M, Ribelles N, Calvo E, Casado A, Marquez A, Vicente D, Garcia-Saenz JA, Martin M (2010) Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat 122:169–176. doi:10.1007/s10549-010-0860-9

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

There is no conflict of interest to disclose.

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, South Korea

    Yeon Hee Park, Jin Seok Ahn & Young-Hyuck Im

  2. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

    Kyung Hae Jung, Jin-Hee Ahn & Sung-Bae Kim

  3. Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea

    Seock-Ah Im, Do Youn Oh & Sae-Won Han

  4. Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

    Joo Hyuk Sohn & Soohyeon Lee

  5. Center for Breast Cancer, National Cancer Center, Goyang, South Korea

    Jungsil Ro, In Hae Park & Keun Seok Lee

  6. Biometric Research Branch, National Cancer Center, Goyang, South Korea

    Byung-Ho Nam

  7. Department of Internal Medicine, Seoul National University Bundang Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seongnam, South Korea

    Jee Hyun Kim

  8. Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, South Korea

    Seok Yun Kang

  9. Department of Internal Medicine, Inha University School of Medicine, Incheon, South Korea

    Moon Hee Lee

  10. Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul, South Korea

    Hee Sook Park

  11. Biostatistics and Clinical Epidemiology Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Sook Young Woo & Sin-Ho Jung

Authors
  1. Yeon Hee Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kyung Hae Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seock-Ah Im
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joo Hyuk Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jungsil Ro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jin-Hee Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sung-Bae Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Byung-Ho Nam
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Do Youn Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sae-Won Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Soohyeon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. In Hae Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Keun Seok Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Jee Hyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Seok Yun Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Moon Hee Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Hee Sook Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Sook Young Woo
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Sin-Ho Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Jin Seok Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Young-Hyuck Im
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Korean Cancer Study Group (KCSG)

Corresponding author

Correspondence to Young-Hyuck Im.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 411 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Park, Y.H., Jung, K.H., Im, SA. et al. Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). Breast Cancer Res Treat 152, 77–85 (2015). https://doi.org/10.1007/s10549-015-3450-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-015-3450-z

Keywords

Search

Navigation